熱門資訊> 正文
Salarius Pharmaceuticals重新遵守纳斯达克最低出价要求
2025-09-09 20:09
- Salarius Pharmaceuticals (NASDAQ:SLRX) on Tuesday said it has received notification from Nasdaq that it has regained compliance with the Minimum Bid Price Requirement.
- As disclosed on August 27, Salarius has until October 20, 2025 to regain compliance with the listing rule.
- On January 13, 2025, Salarius announced it had entered into a definitive merger agreement for a business combination with Decoy Therapeutics. Under the agreement, Decoy will merge with a wholly owned subsidiary of Salarius, subject to the closing conditions set forth in the agreement. The newly formed company will be named Decoy Therapeutics.
- SLRX +7.52% premarket to $5.0.
- Source: Press Release
More on Salarius Pharmaceuticals
- Salarius Pharmaceuticals granted additional extension to regain Nasdaq compliance
- Financial information for Salarius Pharmaceuticals
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
